FDA Expands Use of Pembrolizumab to Two Additional Cancer Types
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab...
Category: In the News
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which pembrolizumab...
For many aspiring investigators, pursuing a career in cancer research can be a complex exploration of self and purpose. In...
This week, President Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act, which is aimed at...
“We are in a promising time for cancer research and treatment; however, ovarian cancer remains difficult to treat, since...
Skin cancer is the most commonly diagnosed cancer in the United States. Every year, about 5 million Americans are...
On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the...
Norman E. “Ned” Sharpless, MD, who became director of the National Cancer Institute in October 2017, recently unveiled areas...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved expanding the use of the immunotherapeutic tisagenlecleucel (Kymriah)...
The AACR Annual Meeting 2018 drew more than 22,600 people to Chicago, providing a front-row seat to some exciting...
Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients...